These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Hormone therapy of eye diseases (review of the literature)]. Margolis MG Vestn Oftalmol; 1967; 80(1):79-84. PubMed ID: 4311943 [No Abstract] [Full Text] [Related]
23. Commentary: unapproved uses, dosages, or indications in dermatology: a physician's reference. Wolf R Clin Dermatol; 2002; 20(5):465-6. PubMed ID: 12435515 [No Abstract] [Full Text] [Related]
24. Off-label use of prescription drugs. Hill M Dermatol Nurs; 2000 Aug; 12(4):238, 256. PubMed ID: 11912659 [No Abstract] [Full Text] [Related]
25. [THE EFFECT OF HORMONES AND ANABOLIC STEROIDS ON GROWTH AND DEVELOPMENT. I. GROWTH HORMONE, THYROID HORMONE, GLUCOCORTICOIDS, ANDROGENIC HORMONES OF THE ADRENAL GLANDS AND GONADS]. GROUGHS W; VISSER HK Ned Tijdschr Geneeskd; 1964 Sep; 108():1797-804. PubMed ID: 14231979 [No Abstract] [Full Text] [Related]
26. Drug treatments for skin disease introduced in 2006. Skin Therapy Lett; 2007 May; 12(4):4-7. PubMed ID: 17551663 [TBL] [Abstract][Full Text] [Related]
27. Hormone treatment of breast cancer. Segaloff A JAMA; 1975 Dec; 234(11):1175-7. PubMed ID: 1242442 [TBL] [Abstract][Full Text] [Related]
30. [Endocrine and cytostatic therapy of metastasizing breast cancer in the female]. Stolzenbach G; Nowakowski H Dtsch Med Wochenschr; 1977 Oct; 102(41):1477-80. PubMed ID: 913282 [No Abstract] [Full Text] [Related]
31. Off-label uses of biologic agents in dermatology: a 2006 update. Kerns MJ; Graves JE; Smith DI; Heffernan MP Semin Cutan Med Surg; 2006 Dec; 25(4):226-40. PubMed ID: 17174843 [TBL] [Abstract][Full Text] [Related]
32. Newer treatment in dermatology. Rees RB South Med J; 1975 Nov; 68(11):1395-1400. PubMed ID: 171775 [TBL] [Abstract][Full Text] [Related]
33. THE VALUE OF HORMONE THERAPY IN GERIATRIC PRACTICE. RICCITELLI ML J Am Geriatr Soc; 1964 Sep; 12():863-7. PubMed ID: 14212059 [No Abstract] [Full Text] [Related]
34. Advances in dermatopharmacology--strength and weakness of recently of approved drugs (I). Chang YC; Maibach HI Int J Clin Pharmacol Ther; 1997 May; 35(5):188-94. PubMed ID: 9174873 [No Abstract] [Full Text] [Related]
35. Miscellaneous treatments, II: niacin and heparin: unapproved uses, dosages, or indications. Wolf R; Orion E; Matz H; Tüzün Y; Tüzün B Clin Dermatol; 2002; 20(5):547-57. PubMed ID: 12435525 [No Abstract] [Full Text] [Related]
38. [Abnormalities of the menstruation cycle and their treatment]. Maneschi M Minerva Ginecol; 1974 Feb; 26(2):95-123. PubMed ID: 4840362 [No Abstract] [Full Text] [Related]
39. Off-label dermatologic therapies. Usage, risks, and mechanisms. Li VW; Jaffe MP; Li WW; Haynes HA Arch Dermatol; 1998 Nov; 134(11):1449-54. PubMed ID: 9828883 [TBL] [Abstract][Full Text] [Related]
40. Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment. Albrecht J; Adamson AS; Barbieri JS; Bennett DD; Kiracofe EA; Kourosh AS; Leslie KS; Merola JF; Nguyen J; Siegfried E; Strickland N; Olbricht S; Asgari MM; J Am Acad Dermatol; 2019 Feb; 80(2):577-578. PubMed ID: 30244066 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]